Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases

• Published in: Journal of Immunology Research Vol. 2019; no. 2019; pp. 1 - 9
• Main Authors: Yin, Geng, Liu, Huan, Sun, Jianhong, Chen, Yuehong, Xie, Qi-bing
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2019; Hindawi; John Wiley & Sons, Inc; Hindawi Limited; Wiley
• Subjects: Antigen (tumor-associated); Antigens; Apoptosis; Autoantibodies; Autoimmune diseases; Autoimmunity; B cells; Belimumab; Chimeric antigen receptors; Chronic diseases; Cytokines; Cytotoxicity; Development and progression; Disease; Drug therapy; Immune system; Immunoglobulins; Immunological tolerance; Immunology; Immunotherapy; Leukemia; Lymphocytes; Lymphocytes T; Lymphoma; Medical treatment; Peptides; Review; T cell receptors; T cells; Tumor cells; Tumor necrosis factor; Tumor necrosis factor-α; Tumors; Womens health
• ISSN: 2314-8861; 2314-7156
• DOI: 10.1155/2019/5727516

Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have been adopted to treat several kinds of malignancies. Autoimmune diseases (AIDs), a class of chronic disease conditions, can be broadly separated into autoantibody-mediated and T cell-mediated diseases. Treatments for AIDs are focused on restoring immune tolerance. However, current treatments have little effect on immune tolerance inverse; even the molecular target biologics like anti-TNFα inhibitors can only mildly restore immune balance. By using the idea of CAR-T cell treatment in tumors, CAR-T cell-derived immunotherapies, chimeric autoantibody receptor T (CAAR-T) cells, and CAR regulatory T (CAR-T) cells bring new hope of treatment choice for AIDs.